Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saravolatz, L.
Right arrow Articles by Belian, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saravolatz, L.
Right arrow Articles by Belian, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 875-877
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae

Louis Saravolatz*,, Odette Manzor, Christine Check, Joan Pawlak and Bradley Belian

Department of Medicine Research Laboratory, St John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, MI, USA

The in vitro and pharmacodynamic effects of moxifloxacin and gatifloxacin against Streptococcus pneumoniae were compared with six other fluoroquinolones. Organisms included penicillin-susceptible (54) and penicillin-non-susceptible (145) isolates from 1998–1999. Moxifloxacin and clinafloxacin demonstrated the greatest in vitro activity, with MIC90s of 0.13 mg/L, followed by trovafloxacin, grepafloxacin > gatifloxacin, sparfloxacin > levofloxacin > ciprofloxacin. There was no difference in fluoroquinolone activity between penicillin-susceptible and -non-susceptible strains. Pharmacodynamic analysis using published pharmacokinetic information indicates that all the agents tested except ciprofloxacin had an AUC/MIC90 > 30, with moxifloxacin having the greatest free-drug availability.

* Corresponding author. Tel: +1-313-343-3362; Fax: +1-313-343-7784; E-mail: louis.saravolatz{at}stjohn.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
V. C. Abraham, D. L. Towne, J. F. Waring, U. Warrior, and D. J. Burns
Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans
J Biomol Screen, July 1, 2008; 13(6): 527 - 537.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Otsu, K. Yanagihara, Y. Fukuda, Y. Miyazaki, K. Tsukamoto, Y. Hirakata, K. Tomono, J.-i. Kadota, T. Tashiro, I. Murata, et al.
In Vivo Efficacy of a New Quinolone, DQ-113, against Streptococcus pneumoniae in a Mouse Model
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3699 - 3703.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.